Ixekizumab - Latest Advances

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

Journal: mAbs

Published: October 19, 2025

Correction to "Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance".

Journal: The Journal of dermatology

Published: October 14, 2025

Correction: Distribution of nailfold videocapillaroscopy parameters in systemic lupus erythematosus and their association with disease activity: an international blinded case-control analysis on behalf of the EULAR study group on microcirculation in rheumatic diseasesEffectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Journal: RMD open

Published: October 09, 2025

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients.

Journal: The Journal of dermatological treatment

Published: October 01, 2025

Evaluation of the serum creatinine to total bilirubin ratio in psoriasis patients treated with biological agents: significant reduction following IL-17 inhibitor therapy.

Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Published: September 30, 2025

A Case of Psoriasis Concurrently Complicated by Sacroiliitis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Journal: Cureus

Published: September 16, 2025

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.

Journal: JAMA dermatology

Published: September 03, 2025

Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Journal: RMD open

Published: August 13, 2025

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Journal: Journal of drugs in dermatology : JDD

Published: August 07, 2025

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: August 06, 2025

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.

Journal: Antibodies (Basel, Switzerland)

Published: August 04, 2025

Classic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis.

Journal: European journal of dermatology : EJD

Published: July 31, 2025

Filters

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

Correction to "Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance".

Correction to "Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance".

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients.

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients.

Evaluation of the serum creatinine to total bilirubin ratio in psoriasis patients treated with biological agents: significant reduction following IL-17 inhibitor therapy.

Evaluation of the serum creatinine to total bilirubin ratio in psoriasis patients treated with biological agents: significant reduction following IL-17 inhibitor therapy.

A Case of Psoriasis Concurrently Complicated by Sacroiliitis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

A Case of Psoriasis Concurrently Complicated by Sacroiliitis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.

Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.

Classic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis.

Classic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis.